Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.61 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.61 |
| ▸ | BRD4 | O60885 | 1/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | IL1B | P01584 | 1/20 | 0.61 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.56 |
| ▸ | AXL | P30530 | 7/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22636509 | 1.00 | CRBN (0.61) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL24142000 | 1.00 | CRBN (0.61) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL19747349 | 1.00 | CRBN (0.61) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL27347582 | 1.00 | CRBN (0.61) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL30438142 | 0.99 | CRBN (0.62) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL19436877 | 0.99 | CRBN (0.62) | CRBNIKZF3DDB1IKZF1BRD4 | |
| Hydrochloric Acid SCHEMBL30772822 | 0.98 | CRBN (0.61) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL21596986 | 0.96 | CRBN (0.63) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL30438018 | 0.96 | CRBN (0.63) | CRBNIKZF3DDB1IKZF1BRD4 | |
| Trifluoroacetic Acid SCHEMBL31326915 | 0.92 | AXL (0.54) | CRBNIKZF3DDB1IKZF1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110615779-B | Process for preparing lenalidomide derivatives | 上海科技大学 | 2023-03-24 | — | — | CN | claimed |
| CN-118908962-A | Heterobifunctional compounds as degradation agents for HPK1 | 西奈山伊坎医学院 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024138128-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4288416-A2 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | The Regents Of The University Of Michigan (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-110615779-B | Process for preparing lenalidomide derivatives | 上海科技大学 | 2023-03-24 | — | — | CN | disclosed |
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| WO-2022169834-A2 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-08-11 | — | — | WO | disclosed |
| CN-114423463-A | Heterobifunctional compounds as HPK1 degradants | 西奈山伊坎医学院 | 2022-04-29 | — | — | CN | disclosed |
| EP-3965824-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | Icahn School of Medicine at Mount Sinai (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020227325-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020069125-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | HIPK1, MCL1, HYPK | CRBN 421/4885IKZF3 1032/4885DDB1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.